


Ledipasvir

ALTERNATE NAME: GS-5885
Harvoni
Methyl N-[(2S)-1-[(6S)-6-[5-[9,9-Difluoro-7-[2-[(1S,2S,4R)-3-[(2S)-2-(methoxycarbonylamino)-3-methylbutanoyl]-3-azabicyclo[2.2.1]heptan-2-yl]-3H-benzimidazol-5-yl]fluoren-2-yl]-1H-imidazol-2-yl]-5-azaspiro[2.4]heptan-5-yl]-3-methyl-1-oxobutan-2-yl]carbamate
GS5885

CATALOG #: B2338-5
B2338-25

AMOUNT: 5 mg
25 mg

STRUCTURE:



MOLECULAR FORMULA: C₄₉H₅₄F₂N₈O₆

MOLECULAR WEIGHT: 889.0

CAS NUMBER: 1256388-51-8

APPEARANCE: Off-white solid

PURITY: ≥98% by HPLC

SOLUBILITY: >10 mg/ml (DMSO)

STORAGE: -20°C

REFERENCES: Link, J.O., et al. (2014). J. Med. Chem. 57, 2033-2046.

DESCRIPTION: Ledipasvir is a potent inhibitor of the hepatitis C virus (HCV) non-structural protein 5A (NS5A) replication complex, with potential activity against HCV. Upon oral administration and after intracellular uptake, ledipasvir binds to and blocks the activity of the NS5A protein. This results in the disruption of the viral RNA replication complex, blockage of HCV RNA production, and inhibition of viral replication. It failed to inhibit SARS-CoV-2 replication *in vitro*.

HANDLING: Do not take internally. Wear gloves and mask when handling the product! Avoid contact by all modes of exposure.

RELATED PRODUCTS:

Ribavirin (2199)
Danoprevir (B2184)
Telaprevir (B1235)
Acyclovir (2200)
Zanamivir (B1900)
Velpatasvir (B1194)
Ritonavir (B2140)
Simeprevir (B1173)

DISCLAIMER: FOR RESEARCH USE ONLY! Not to be used on humans.

